[go: up one dir, main page]

WO2017136696A1 - Procédés et appareil destinés au traitement de biomarqueurs ophtalmiques - Google Patents

Procédés et appareil destinés au traitement de biomarqueurs ophtalmiques Download PDF

Info

Publication number
WO2017136696A1
WO2017136696A1 PCT/US2017/016463 US2017016463W WO2017136696A1 WO 2017136696 A1 WO2017136696 A1 WO 2017136696A1 US 2017016463 W US2017016463 W US 2017016463W WO 2017136696 A1 WO2017136696 A1 WO 2017136696A1
Authority
WO
WIPO (PCT)
Prior art keywords
retinal
biomarkers
biomarker
patient
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/016463
Other languages
English (en)
Inventor
Archana MURALI
Elena Berman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2017136696A1 publication Critical patent/WO2017136696A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/0016—Operational features thereof
    • A61B3/0025—Operational features thereof characterised by electronic signal processing, e.g. eye models
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/0002—Inspection of images, e.g. flaw detection
    • G06T7/0012—Biomedical image inspection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/40—ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/102—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for optical coherence tomography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0062—Arrangements for scanning
    • A61B5/0066—Optical coherence imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/10—Image acquisition modality
    • G06T2207/10072—Tomographic images
    • G06T2207/10088—Magnetic resonance imaging [MRI]
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/10—Image acquisition modality
    • G06T2207/10072—Tomographic images
    • G06T2207/10101—Optical tomography; Optical coherence tomography [OCT]
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/10—Image acquisition modality
    • G06T2207/10072—Tomographic images
    • G06T2207/10104—Positron emission tomography [PET]
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/20—Special algorithmic details
    • G06T2207/20072—Graph-based image processing
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30004—Biomedical image processing
    • G06T2207/30041—Eye; Retina; Ophthalmic
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30004—Biomedical image processing
    • G06T2207/30084—Kidney; Renal

Definitions

  • Embodiments of the present disclosure relate generally to the field of systems for medical image processing, particularly to systems for ophthalmic medical images for use in diagnosis of neurodegenerative disease.
  • Neurodegenerative diseases such as Alzheimer's and Parkinson's disease are debilitating and incurable conditions that cause the progressive degeneration of neurons cells. These diseases affect millions of people worldwide, and the economic costs of these disorders are comparably high. Reports in 2010 estimated the global cost of patient care for neurological diseases to be $6 trillion in 2030. Unfortunately, despite the overwhelming need for reliable and affordable patient care, diagnostic methods and treatments for many neurodegenerative diseases are not effective or accurate. Accurate methods of diagnosing and monitoring the progression of these diseases are crucial for the development of new medications.
  • hippocampal complex and entorhinal complex are commonly known to be sites of early disease pathology in the brain, but recently the retina has been shown to be affected by neurological diseases. Research has even suggested that signs of neurodegenerative diseases in the retina occur even earlier than they occur in the brain. Studies have suggested that anterior visual pathways are affected by these diseases, as shown by degeneration in the retina.
  • Alzheimer's disease is a neurodegenerative disorder that affects currently 46 million people in the world and is expected to affect 131.5 million people by the year 2050. Alzheimer's is the most common form of dementia. Other types of dementia include vascular dementia, dementia with Lewy bodies, mixed dementia, frontotemporal dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus dementia, Huntington's disease, and Wernicke- Korsakoff syndrome.
  • Alzheimer's Although there have been numerous studies to determine what causes Alzheimer's, these studies are not definitive. Studies of Alzheimer's suggest that Alzheimer's is caused by a build up of different substances in the brain such as tau proteins that spur neuronal death, ⁇ - amyloid plaque, which are toxic to neurons, and neurofibrillary tangles that damage the ability of neurons to communicate with each other. Unfortunately, even though there have been numerous studies conducted on the causes and possible treatments for Alzheimer's, medications that are used to treat Alzheimer's fail to stop or slow the progression of the disease. Instead, these drugs focus on treating the symptoms of Alzheimer's, such as reduced thinking ability and anxiety.
  • CT computed tomography
  • MRI magnetic resonance imaging
  • PET positron emission tomography
  • these imaging methods do not provide sufficient molecular specificity to detect amyloid plaques, neurofibrillary tangles or tau tangles.
  • these tests are only 75% accurate and have a high risk for false positives and false negatives.
  • amyloid imaging is restricted to very few specialized research centers and the cost of this imaging is prohibitive.
  • Alzheimer's patient has likely entered later, more severe stages of the disease where severe brain damage has already occurred because many patients go to neurologists only after they start showing a reduction in cognitive function, which occurs many years after physical signs of Alzheimer's occur. Studies have suggested that signs of Alzheimer's in the brain occur when patients are as young as 20.
  • Parkinson's disease (or simply "Parkinson's” or “PD”) is a neurodegenerative condition that causes progressive and chronic movement disorders, along with cognitive, autonomic, and visual dysfunctions.
  • Parkinson's affects more than 10 million people in the world. It is predicted to cost the United States $25 billion per year. Parkinson's patients pay an average of $2500 per year for checkups and about $100,000 for surgery.
  • Surgical techniques can include deep brain stimulation, thalomotomy, pallidotomy, and subthalamotomy. The causes of Parkinson's are unknown despite numerous and extensive studies.
  • researchers know that patients risk for contracting Parkinson's increases as they age and for most patients, Parkinson's progresses slowly and continues to worsen over time. This is also true for Alzheimer's.
  • Parkinson's is often monitored by analyzing brain scans for nerve cell death and an increase in the protein alpha-synuclein (also called Lewy Bodies).
  • Biomarkers are measurable substances or features in an organism, the presence or dimensions of which may be indicative of some phenomenon such as disease, infection, or environmental exposure. Biomarkers can also include measures of strength, mood, or mental acuity. Research has suggested that ocular biomarkers (especially the sizes of various features of retina) may be indicative of neurological diseases such as Alzheimer's or Parkinson's.
  • the ability to accurately and efficiently measure biomarkers can assist in the diagnosis of various neurodegenerative diseases.
  • a retinal biomarker processing system comprises an image processor configured to receive image data corresponding to a patient and depicting at least one retinal image, the at least one retinal image having a scale a pixel size of one or more retinal biomarkers, a measurement analyzer configured to determine an absolute size of each of the one or more retinal biomarkers, a biomarker database configured to store each of the absolute sizes of each of the one or more retinal biomarkers, a biomarker analyzer configured to calculate a score related to a health outcome for the patient based on the absolute size of at least one of the one or more retinal biomarkers, and a user interface configured to produce an output related to the score.
  • the system presents user interface elements enabling a user to identify and measure one or more biomarkers in each image by asking the user to input the scale of the image, converting the pixels of the image to the user's preferred scale, asking the user to then indicate the top and the bottom the retinal biomarker to measure, collecting the x and y coordinates of the user's indications, displaying a line between the two points that the user clicked on the image to show the user what line would be measured and converting this highlighted length in pixels to an actual length for display and processing.
  • the indicator related to the probability of the patient having a neurological disease for the patient is determined by by determining a disease range and a control range for the absolute size or the rate of change of at least one of the one or more retinal biomarkers, assigning a score for each one of the at least one retinal biomarkers based on whether the absolute size or the rate of change over time of the retinal biomarker is within the disease range for the absolute size or the rate of change over time of the retinal biomarker, the control range for the absolute size or the rate of change over time of the retinal biomarker, or outside of both ranges for the absolute size or the rate of change over time of the retinal biomarker and selecting the indicator related to the health outcome based on the sum of scores of each of the at least one retinal biomarkers.
  • FIG. 1 is a screenshot depicting an annotated scan of an eye
  • FIG. 2 is a block diagram depicting a schematic view of various engines and components of a retinal biomarker processing system, according to an embodiment
  • FIG. 3 is a screenshot depicting a screen of a user interface, according to an embodiment
  • FIG. 4A is a screenshot depicting a screen of a user interface, according to an embodiment
  • FIG. 4B is a screenshot depicting a screen of a user interface, according to an embodiment
  • FIG. 4C is a screenshot depicting a screen of a user interface, according to an embodiment
  • FIG. 5A is a block diagram depicting raw measurement data elements, according to an embodiment
  • FIG. 5B is a block diagram depicting data elements of a scan record, according to an embodiment
  • FIG. 6 is a graph depicting the change in various retinal biomarkers in patients over time.
  • FIG. 7 is a flowchart depicting a method for determining a biomarker score, according an embodiment.
  • FIG. 1 is an annotated image depicting an end on, or front, scan 102a of an eye and a selected cross-section scan 102b of the same eye of the type that can be received by embodiments.
  • scans (or retinal images) 102a and 102b were produced by an optical coherence tomography (OCT) scanning device manufactured by Heidelberg Engineering, however scans 102 can be produced by a number of other devices known in the art.
  • OCT optical coherence tomography
  • any image capture method suitable to render accurate scale images of the retina and associated biomarkers can be used.
  • biomarkers 104 can include retinal (or central) vein 104a, nerve fiber layer 104b, ganglion cell layer 104c, and choroid 104d. In embodiments, more, fewer, or alternate biomarkers 104 can be analyzed. For example, in embodiments, other biomarkers such as optic disk cupping, optic disk coloration, and optic nerve thickness may be used instead over, or in combination with the biomarkers discussed herein. Also depicted in scans 102a and 102 are scale indicators 106a and 106b, legend 108, and eye indicator, 110.
  • FIG. 2 is a block diagram depicting various engines (or components) of retinal biomarker processing system 100, according to an embodiment.
  • retinal biomarker processing system 100 can comprise a user interface 120, an image processor 122, a measurement analyzer 124, a biomarker analyzer 126, and a biomarker database 128.
  • Scans 102 are received by an image processor 122.
  • Scans 102 generally comprise one or more image files.
  • image processor 122 can receive multiple disparate image file formats such as portable network graphics (PNG) files, graphics interchange format (GIF) files, joint photographic experts group (JPEG or JPG) files, tag image file format (TIFF), or other file formats.
  • Scans 102 can be received from a local permanent or removable storage medium, over a network connection, such as from an electronic medical record (EMR) system, or via a direct connect to a device capable of producing scans 102.
  • image processor 122 can be configured to receive data from local or remote systems using provided application programming interface (API) methods.
  • image processor 122 can convert scans 102 to data formats appropriate for use by other engines of system 100.
  • API application programming interface
  • image processor 122 can decode or receive metadata associated with scans 102.
  • image processor 122 can decode metadata that is embedded within scans 102 as exchangeable image file format (Exif) or extensible metadata platform XMP data or other embedded metadata formats.
  • image processor 122 can receive metadata from the network or other source of scans 102, for example as associated data files or as data returned via an API.
  • metadata can be entered via user interface 120 (discussed in more detail below), or can be retrieved from one or more remote systems.
  • Metadata can include data related to the patient, such as an identifier, demographic information such as gender and age, and the patient's medical history. Metadata can also include data related to the scan 102, such as the scan resolution and scale, the equipment used to create the scan, and the date and/or time stamp information related to the creation of the scan.
  • User interface 120 is configured to allow interaction between a user and the various components and engines of biomarker processing system 100.
  • User interface 120 enables the user to provide scan information to image processor 122 (such as, for example, the file name or network location of a scan 102), and can display scans 102 and other information to user.
  • User interface 120 can comprise a graphical user interface (GUI), a web based interface for access via a web browser, a command line interface, or a programmatic interface such as an application programming interface (API).
  • GUI graphical user interface
  • API application programming interface
  • User interface 120 can receive user input via a network connection, keyboard, touchscreen, mouse, joystick, or any other input device.
  • FIGS. 3-4 are screenshots depicting various example screens that may be presented by user interface 120, in embodiments. Those of ordinary skill in the art will recognize that the depicted screens are merely examples, and the screens of user interface 120 can be presented with a variety of looks and feels different than those shown.
  • FIG. 3 is a screen shot of a biomarker measurement screen 400 presented by user interface 120 in an embodiment.
  • Screen 400 presents a scan 102 and various selectable functions 402.
  • Functions 402 can include scale function 404.
  • scale function 404 When scale function 404 is selected by the user, user interface 120 can request that the user enter the scale directly (for example, by providing data entry stating that each pixel in scan 102 has an actual size of 3.9 ⁇ ) in embodiments.
  • user interface 120 can assist the user in determining the scale. For example, user interface 120 can request that the user indicate an upper and a lower boundary of a scale line 406 within the scan 102 (such as scales 106a and 106b of FIG. 1) using mouse clicks, mouse strokes, or other input methods.
  • User interface 120 can also request that the user provide the actual size in micrometers of the scale line (for example, 200 ⁇ ).
  • Scale dialog 405 which can display and enable user input of distance in pixels, known distance, aspect ratio and units can be present in embodiments.
  • user interface 120 can confirm the scale (in ⁇ /pixel) at scale output 408.
  • user interface 120 can enable the user to zoom in or out of scan 102, and present scaled lines and measurements as appropriate.
  • user interface 120 can request that the user provide entry regarding which biomarker 104 is being measured.
  • user interface 120 can present a list of biomarkers 104 available, or may allow free text entry.
  • User interface 120 can then request that the user indicate a starting and an ending boundary of a measurement line 412.
  • the actual size of the biomarker 104 can then be determined by multiplying the size of measurement line 412 in pixels by scale.
  • the actual length of the measurement line can be indicated to the user at measurement output 414.
  • FIGS. 4A-4C present an alternative screen 400' of user interface 120 for enabling user entry of biomarker measurements in embodiments.
  • measurement function 410 is selected by the user
  • user interface 120 can request that the user indicate an upper and a lower boundary of a gradient line 414.
  • gradient line 414 need only extend beyond the boundaries of any feature of interest, as opposed to ending at a specific upper and lower point of a biomarker 104.
  • User interface 120 can then present gradient graph 416 which, in embodiments, represents the actual length of gradient line 414 as the x-axis and the gray value of the pixels along the actual length of the gradient line 414 as the y-axis.
  • the gray value is useful for determining the boundaries of features in black and white or grayscale scans 102.
  • other values that can be detected from scan 102 can be used, such as a hue, saturation, total value or transparency level of each pixel, or the values of each pixel in the red, green, or blue channels, or cyan, magenta, yellow, and black channels.
  • Graph 416 can enable the user to determine the boundaries of features and biomarkers 140 based on the local minimums, maximums, and slope of the curve. Generally, in OCT scans 102 such as those depicted herein, the gray value curve will exhibit steep slopes at feature boundaries.
  • User interface 120 can then enable the user to select the start and end points of a graph measurement line 418 on graph 416, indicating the actual length of the feature being measured as seen in FIG. 4B.
  • the actual length of measurement line 420 can be indicated to the user.
  • the correspondence between graph measurement line 418 and scan 102 can be depicted directly on scan 102 as seen in FIG. 4C, where multiple graph measurement lines 420 are indicated on scan 102.
  • the values plotted on graph 416 can be used to double check the entry by the user. For example, if the user plots graph measurement line 418, across multiple boundaries with steep slope, user interface 120 can request that the user confirm the selections.
  • graph 416 can be used to compute possible boundaries for presentation and confirmation by the user, in embodiments.
  • the graph-based measurement functionality of FIGS. 4A-4C can enable easier user entry of measurements, where the boundary lines between features in scan 102 may be difficult to see or select accurately.
  • user interface 120 can enable the user to enter data associated with a test of mental state, for example a Mini-Mental State Examination (MMSE).
  • MMSE Mini-Mental State Examination
  • user interface 120 can present test questions and receive answers.
  • user interface 120 can enable the user to enter a total score.
  • FIG. 5A is a block diagram depicting a schematic view of raw measurement data 200, according to embodiments.
  • Raw measurement data is populated by measurement analyzer 124 in embodiments.
  • raw measurement data 200 can include a mental state score provided by the user, or calculated from the test answers received by user interface 120.
  • raw measurement data can include the actual (or "absolute") sizes of one or more biomarkers 104 within scan 102.
  • raw measurement data 200 can include the mental state score
  • measurement analyzer 124 can determine the boundaries of a biomarker 104 or other feature within the image and determine the actual size of the biomarker 104 or other feature based on the scan resolution and scale.
  • measurement analyzer 124 can detect the location and sizes of features within scan 102 automatically. In other embodiments, measurement analyzer 124 can receive feature size information via user interface 120. While raw measurement data 200 includes nerve fiber layer width 202, choroid width 204, retinal vein diameter 206, ganglion cell layer width 208 and mental state score 210, in the embodiment of FIG 5 A, other data structures can of course be used, especially in embodiments of system 100 configured to process alternative sets of biomarkers.
  • biomarker database 128 is configured to score scan records 300, as depicted in FIG. 5B.
  • Each scan record 300 can include patient related data, such as a patient identifier 302, patient demographic data 304 (such as patient age or gender), and patient medical history 306.
  • patient related data can be anonymized, such that patient identifier 302 need not comprise information that can allow a patient identifier 302 and/or the associated scans to be linked to an actual patient within biomarker database 128.
  • patient identifier 302 can be a randomly generated identifier, linked to the patient within another system, or not linked to any particular patient at all.
  • Patient medical history 306 can include one or more indicators regarding ocular or other disease diagnoses that may affect the analysis of raw measurement data 200.
  • health outcome indications can be modified based on the patient having medical history including indications of age-related macular degeneration (AMD), or glaucoma.
  • Each scan record 300 can also include scan related data including an indication of which eye has been scanned 308, and scan date 310 (which can also include time stamp information).
  • Each scan record 300 can further include calculated data such as raw measurement data 200, outcome indicators 312 and biomarker scores 314. More, fewer, and alternative data items can be stored within biomarker database 128 in embodiments.
  • biomarker database 128 can comprise any data storage device(s) or system(s), suitable for storage of scan records 300 and retrieval of same by biomarker analyzer 126.
  • biomarker database can comprise, for example, local hard drives, removable storage media, and local or remote database systems.
  • Scan records 300 in biomarker database 128 can be retrievable by patient identifier 302, eye 308, scan date 310, or any other data element of scan record 300.
  • any or all of patient related data items 302, 304, 306 and scan related data items 308 and 310 can be determined from metadata provided by image processor 122.
  • biomarker database 128 can determine some or all of patient related data items 304 and 306 based on a provided patient identifier 302 and one or more stored scan records 300, or other data associated with the provided patient identifier 302.
  • user interface 120 can enable the user to modify each data item of each scan record 300 within biomarker database 128.
  • Biomarker analyzer 126 can evaluate raw measurement data 200 from one or more scans 102 to determine one or more health outcomes indicated by biomarkers 104, in embodiments. In embodiments, biomarker analyzer 126 can determine one or more outcome indicators 312, each related to the likelihood that the patient associated with the raw measurement data 200 has a neurodegenerative disease such as Alzheimer's or Parkinson's. In embodiments, outcome indicators 312 can be related to whether the scans 102 are indicative of neurodegenerative disease.
  • outcome indicators 312 can be determined by first determining one or more biomarker scores 314 for each biomarker based both on the biomarker measurement and patient medical history.
  • Biomarker scores 314 for a disease can be determined based on defined disease and control ranges in embodiments. For example, in an embodiment, disease ranges for Alzheimer's and Parkinson's can be defined as shown in Table 1 below for patients with and without age-related macular degeneration. As depicted in Table 1 below, not all biomarkers 104 must be used, and in embodiments, choroid layer thickness is not considered in the determination of an outcome indicator 312 for Parkinson's.
  • biomarker scores 314 can be determined at least in part based on measurements of biomarkers over time, using the scan date 310.
  • the rate of change can be calculated based on, for example, the slope of a linear regression of scans of the same eye of the same patient over a period of time, as depicted in FIG. 6 for individual patients known to have Alzheimer's, Parkinson's or neither (control). Other methods of determining the rate of change based on a series of scans 102 can be used in embodiments.
  • the disease ranges for the rate of change of biomarkers for Alzheimer's and Parkinson's can be defined as shown in Table 2 below, for patients with and without age- related macular degeneration.
  • FIG 7 is a flowchart depicting a method 700 for determining a biomarker score 314 in embodiments.
  • the biomarker score for that disease is assigned the value of 1.0 at 704. If not, but the biomarker is within the control range at 406, the biomarker score is assigned the value of 0.0 at 708.
  • the biomarker score is assigned the value of 0.5 at 712.
  • the exception handling can be performed.
  • Exception handling can include reporting an error message to the user, or setting a biomarker score of 0.0 or 0.5, in embodiments or a combination of these.
  • the method of exception handling can vary based on the disease, and be configurable in the same methods as described above for biomarker ranges.
  • other weightings or values for biomarker scores 314 can be used, for example as discussed above choroid layer thickness may be disregarded in determining an outcome indicator 312 for Parkinson's.
  • method 700 can be similarly applied to the rate of change of biomarker measurements over time.
  • a mental state score can be used to provide an additional biomarker score 314.
  • a severe disease range for Alzheimer's can be between 1 and 12 points and the biomarker score can be set to 1.5
  • a moderate disease range can be between 13 and 20 points and the biomarker score can be set to 1.0
  • a mild disease range can be between 20 and 24 points and the biomarker score can be set to 0.5.
  • Other point values and scores can be used in embodiments.
  • outcome indicators 312 for each disease can be determined based on the biomarker scores.
  • an Alzheimer's outcome indicator 310 can be determined based on the sum of the Alzheimer's biomarker scores 314, for each biomarker 104a-104d.
  • a Parkinson's outcome indicator can be determined based on the sum of the Parkinson's biomarker scores 310 for biomarkers 104a-104c (disregarding choroid layer 104d).
  • Table 3 includes details of outcome indicators 314 for Alzheimer's and Parkinson's that can be used in embodiments.
  • outcome indicators 312 can be determined using other combinations of biomarker scores 314.
  • outcome indicators 312 can be determined based on mental state score 210 and the rates of change of any value tracked in raw measurement data 200 for the same patient over time. Therefore in embodiments, outcome indicators 312 can be determined based on combinations of any number of biomarker scores 314, any number of elements of raw measurement data 200, and the rates of change in any number of biomarker scores 314 or any number of elements of raw measurement data 200 for the same patient over time.
  • ranges, scores, and outcomes of Tables 1 , 2, and 3 above correspond to values determined from patient data.
  • ranges, scores, and outcomes can be used in embodiments, including ranges, scores, and outcomes for one or more other neurological diseases such as multiple sclerosis, and based on other patient details such as age, gender, or other ocular conditions (such as glaucoma).
  • disease ranges, scores, and outcomes can be defined within biomarker analyzer
  • Embodiments of the present disclosure have been used to review a total of 4,675 OCT retinal scans from 379 patients with known neurological disease status. The patients were sorted into age-matched groups of those diagnosed with Alzheimer's (AD patient group), those diagnosed with Parkinson's (PD patient group), and those without AD or PD (control group). The age ranges for each test group were compared to ensure that the groups were age- matched.
  • the patients' OCT scans were processed to determine actual biomarker sizes, oneway analyses of variance (ANOVAs) were run and 95% confidence intervals were calculated for the biomarker measurements and the average rate of change of the biomarkers for patients among all six test groups (AD patient group, AD with age-related macular degeneration patient group, PD patient group, PD with age-related macular degeneration patient group, control patient group, and control with age-related macular degeneration patient group).
  • the 95% confidence intervals for each test group for each retinal biomarker 104, and the rate of change of change in retinal biomarkers 104 provided the disease and control ranges listed in Tables 1 and 2 above.
  • Tests have shown that embodiments of the present disclosure using the disease ranges and scoring of Tables 1 through 3 above were 99% accurate in identifying patients with a diagnosis of Alzheimer's in their medical records and who are currently taking an Alzheimer's medication, 97% accurate in identifying patients with a diagnosis of Parkinson's in their medical records and who are currently taking a Parkinson's medication, and 97% accurate in identifying patients with no serious cognitive diseases documented in their medical records and who are not taking Alzheimer's or Parkinson's medications.
  • Embodiments of the present disclosure can enable efficient and low-cost detection of biomarker dimensions, which can have significant clinical and research benefits.
  • Embodiments of the present disclosure can assist in the diagnosis of Alzheimer's and Parkinson's or other neurodegenerative diseases without the need for expensive MRI scans. This can facilitate more prophylactic screening of patients before symptoms of neurodegenerative disease are present.
  • Embodiments of the present disclosure can also enable help to lower the cost of tracking the progression of already-diagnosed disease because less MRI imaging may be required.
  • Embodiments of the present disclosure can also be used to discover additional correlations between retinal biomarkers and other diseases.
  • the biomarker processing system 100 and/or its components or subsystems can include computing devices, microprocessors, modules and other computer or computing devices, which can be any programmable device that accepts digital data as input, is configured to process the input according to instructions or algorithms, and provides results as outputs.
  • computing and other such devices discussed herein can be, comprise, contain or be coupled to a central processing unit (CPU) configured to carry out the instructions of a computer program. Computing and other such devices discussed herein are therefore configured to perform basic arithmetical, logical, and input/output operations.
  • CPU central processing unit
  • Memory can comprise volatile or non-volatile memory as required by the coupled computing device or processor to not only provide space to execute the instructions or algorithms, but to provide the space to store the instructions themselves.
  • volatile memory can include random access memory (RAM), dynamic random access memory (DRAM), or static random access memory (SRAM), for example.
  • non-volatile memory can include read-only memory, flash memory, ferroelectric RAM, hard disk, floppy disk, magnetic tape, or optical disc storage, for example.
  • system or components thereof can comprise or include various modules or engines, each of which is constructed, programmed, configured, or otherwise adapted to autonomously carry out a function or set of functions.
  • modules or engines each of which is constructed, programmed, configured, or otherwise adapted to autonomously carry out a function or set of functions.
  • engine as used herein is defined as a real-world device, component, or arrangement of components implemented using hardware, such as by an application specific integrated circuit (ASIC) or field- 10 programmable gate array (FPGA), for example, or as a combination of hardware and software, such as by a microprocessor system and a set of program instructions that adapt the engine to implement the particular functionality, which
  • ASIC application specific integrated circuit
  • FPGA field- 10 programmable gate array
  • An engine can also be implemented as a combination of the two, with certain functions facilitated by hardware alone, and other functions facilitated by a combination of hardware and software.
  • at least a portion, and in some cases, all, of an engine can be executed on the processor(s) of one or more computing platforms that are made up of hardware (e.g., one or more processors, data storage devices such as memory or drive storage, input/output facilities such as network interface devices, video devices, keyboard, mouse or touchscreen devices, etc.) that execute an operating system, system programs, and application programs, while also implementing the engine using multitasking, multithreading, distributed (e.g., cluster, peer-peer, cloud, etc.) processing where appropriate, or other such techniques.
  • hardware e.g., one or more processors, data storage devices such as memory or drive storage, input/output facilities such as network interface devices, video devices, keyboard, mouse or touchscreen devices, etc.
  • multitasking multithreading
  • distributed e.g., cluster, peer-peer, cloud, etc.
  • each engine can be realized in a variety of physically realizable configurations, and should generally not be limited to any particular implementation exemplified herein, unless such limitations are expressly called out.
  • an engine can itself be composed of more than one sub-engines, each of which can be regarded as an engine in its own right.
  • each of the various engines corresponds to a defined autonomous functionality; however, it should be understood that in other contemplated embodiments, each functionality can be distributed to more than one engine.
  • multiple defined functionalities may be implemented by a single engine that performs those multiple functions, possibly alongside other functions, or distributed differently among a set of engines than specifically illustrated in the examples herein.
  • embodiments may comprise fewer features than illustrated in any individual embodiment described above.
  • the embodiments described herein are not meant to be an exhaustive presentation of the ways in which the various features may be combined. Accordingly, the embodiments are not mutually exclusive combinations of features; rather, embodiments can comprise a combination of different individual features selected from different individual embodiments, as understood by persons of ordinary skill in the art.
  • elements described with respect to one embodiment can be implemented in other embodiments even when not described in such embodiments unless otherwise noted.
  • a dependent claim may refer in the claims to a specific combination with one or more other claims, other embodiments can also include a combination of the dependent claim with the subject matter of each other dependent claim or a combination of one or more features with other dependent or independent claims. Such combinations are proposed herein unless it is stated that a specific combination is not intended.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Developmental Disabilities (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Signal Processing (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Artificial Intelligence (AREA)
  • Quality & Reliability (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un procédé et un système de traitement de biomarqueur rétinien. Les modes de réalisations de la présente invention comprennent : un processeur d'image afin de recevoir les données d'image correspondantes à un patient, l'image ayant une échelle et un emplacement de pixel et une taille de pixel d'au moins un biomarqueur rétinien, un analyseur de mesure conçu afin de déterminer une taille absolue desdits biomarqueurs rétiniens, un analyseur de biomarqueur conçu afin de déterminer un indicateur relié au résultat clinique destiné au patient basé sur la taille absolue d'au moins un desdits biomarqueurs rétiniens. Dans les modes de réalisation, l'utilisateur identifie la taille d'au moins un biomarqueur en cliquant sur les emplacements de pixel qui sont converties en emplacements absolus. Dans les modes de réalisation de la présente invention, une probabilité de maladie neurologique chez le patient peut être déterminée.
PCT/US2017/016463 2016-02-05 2017-02-03 Procédés et appareil destinés au traitement de biomarqueurs ophtalmiques Ceased WO2017136696A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291925P 2016-02-05 2016-02-05
US62/291,925 2016-02-05

Publications (1)

Publication Number Publication Date
WO2017136696A1 true WO2017136696A1 (fr) 2017-08-10

Family

ID=59500253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/016463 Ceased WO2017136696A1 (fr) 2016-02-05 2017-02-03 Procédés et appareil destinés au traitement de biomarqueurs ophtalmiques

Country Status (1)

Country Link
WO (1) WO2017136696A1 (fr)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111655151A (zh) * 2018-01-25 2020-09-11 国立大学法人大阪大学 压力状态的检测方法以及压力检测装置
US11534323B2 (en) 2017-12-22 2022-12-27 Coloplast A/S Tools and methods for placing a medical appliance on a user
US11540937B2 (en) 2017-12-22 2023-01-03 Coloplast A/S Base plate and sensor assembly of a medical system having a leakage sensor
US11547595B2 (en) 2017-12-22 2023-01-10 Coloplast A/S Base plate and a sensor assembly part for a medical appliance
US11547596B2 (en) 2017-12-22 2023-01-10 Coloplast A/S Ostomy appliance with layered base plate
US11590015B2 (en) 2017-12-22 2023-02-28 Coloplast A/S Sensor assembly part and a base plate for a medical appliance and a method for manufacturing a sensor assembly part and a base plate
US11589811B2 (en) 2017-12-22 2023-02-28 Coloplast A/S Monitor device of a medical system and associated method for operating a monitor device
US11607334B2 (en) 2017-12-22 2023-03-21 Coloplast A/S Base plate for a medical appliance, a monitor device and a system for a medical appliance
US11612508B2 (en) 2017-12-22 2023-03-28 Coloplast A/S Sensor assembly part for a medical appliance and a method for manufacturing a sensor assembly part
US11628084B2 (en) 2017-12-22 2023-04-18 Coloplast A/S Sensor assembly part and a base plate for a medical appliance and a device for connecting to a base plate or a sensor assembly part
US11627891B2 (en) * 2017-12-22 2023-04-18 Coloplast A/S Calibration methods for medical appliance tools
US11654043B2 (en) 2017-12-22 2023-05-23 Coloplast A/S Sensor assembly part and a base plate for a medical appliance and a method for manufacturing a base plate or a sensor assembly part
US11701248B2 (en) 2017-12-22 2023-07-18 Coloplast A/S Accessory devices of a medical system, and related methods for communicating leakage state
US11707376B2 (en) 2017-12-22 2023-07-25 Coloplast A/S Base plate for a medical appliance and a sensor assembly part for a base plate and a method for manufacturing a base plate and sensor assembly part
US11707377B2 (en) 2017-12-22 2023-07-25 Coloplast A/S Coupling part with a hinge for a medical base plate and sensor assembly part
US11717433B2 (en) 2017-12-22 2023-08-08 Coloplast A/S Medical appliance with angular leakage detection
US11737907B2 (en) 2019-01-31 2023-08-29 Coloplast A/S Moisture detecting base plate for an ostomy appliance and a system for determining moisture propagation in a base plate and/or a sensor assembly part
US11786392B2 (en) 2017-12-22 2023-10-17 Coloplast A/S Data collection schemes for an ostomy appliance and related methods
US11819443B2 (en) 2017-12-22 2023-11-21 Coloplast A/S Moisture detecting base plate for a medical appliance and a system for determining moisture propagation in a base plate and/or a sensor assembly part
US11865029B2 (en) 2017-12-22 2024-01-09 Coloplast A/S Monitor device of a medical system having a connector for coupling to both a base plate and an accessory device
US11872154B2 (en) 2017-12-22 2024-01-16 Coloplast A/S Medical appliance system, monitor device, and method of monitoring a medical appliance
US11918506B2 (en) 2017-12-22 2024-03-05 Coloplast A/S Medical appliance with selective sensor points and related methods
US11931285B2 (en) 2018-02-20 2024-03-19 Coloplast A/S Sensor assembly part and a base plate for a medical appliance and a device for connecting to a base plate and/or a sensor assembly part
US11986418B2 (en) 2017-12-22 2024-05-21 Coloplast A/S Medical system and monitor device with angular leakage detection
US11998473B2 (en) 2017-12-22 2024-06-04 Coloplast A/S Tools and methods for cutting holes in a medical appliance
US11998474B2 (en) 2018-03-15 2024-06-04 Coloplast A/S Apparatus and methods for navigating ostomy appliance user to changing room
US12029582B2 (en) 2018-02-20 2024-07-09 Coloplast A/S Accessory devices of a medical system, and related methods for changing a medical appliance based on future operating state
US12064258B2 (en) 2018-12-20 2024-08-20 Coloplast A/S Ostomy condition classification with image data transformation, devices and related methods
US12064369B2 (en) 2017-12-22 2024-08-20 Coloplast A/S Processing schemes for an ostomy system, monitor device for an ostomy appliance and related methods
US12147357B2 (en) 2020-04-14 2024-11-19 Coloplast A/S Personal care system with monitor device and related methods
US12165312B2 (en) 2018-12-20 2024-12-10 Coloplast A/S Ostomy condition classification with masking, devices and related methods
US12171572B2 (en) 2017-12-22 2024-12-24 Coloplast A/S Accessory devices of a medical system, and related methods for communicating operating state
US12178740B2 (en) 2017-12-22 2024-12-31 Coloplast A/S Leakage detection in an ostomy device
US12208029B2 (en) 2018-02-20 2025-01-28 Coloplast A/S Base plate having a mechanical and electrical connector
US12226229B2 (en) 2018-03-15 2025-02-18 Coloplast A/S Methods of configuring ostomy notifications and related accessory devices
US12232997B2 (en) 2018-08-15 2025-02-25 Coloplast A/S Accessory device of a medical system and related methods for issue identification
US12232998B2 (en) 2019-01-31 2025-02-25 Coloplast A/S Application of a stomal sensor patch
US12257172B2 (en) 2019-02-28 2025-03-25 Coloplast A/S Sensor patch for attachment to a base plate
US12272449B2 (en) 2017-12-22 2025-04-08 Coloplast A/S Data transmission schemes for a medical system, monitor device for a medical appliance and related methods
US12310877B2 (en) 2019-01-31 2025-05-27 Coloplast A/S Sensor patch for an ostomy appliance
US12376984B2 (en) 2019-01-31 2025-08-05 Coloplast A/S Stomal sensor patch
US12453649B2 (en) 2018-03-15 2025-10-28 Coloplast A/S Apparatus and methods for determining medical appliance wear time based on location data
US12458278B2 (en) 2015-12-23 2025-11-04 Coloplast A/S Moisture assessment system and method for wound care
US12484845B2 (en) 2018-03-15 2025-12-02 Coloplast A/S Methods for managing remaining wear time of a medical appliance and related accessory devices

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035187A1 (en) * 2009-01-29 2012-02-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Anti-neurodegenerative disease agent
US20150029464A1 (en) * 2013-07-26 2015-01-29 The Regents Of The University Of Michigan Automated Measurement of Changes in Retinal, Retinal Pigment Epithelial, or Choroidal Disease
US20150110372A1 (en) * 2013-10-22 2015-04-23 Eyenuk, Inc. Systems and methods for automatically generating descriptions of retinal images

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035187A1 (en) * 2009-01-29 2012-02-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Anti-neurodegenerative disease agent
US20150029464A1 (en) * 2013-07-26 2015-01-29 The Regents Of The University Of Michigan Automated Measurement of Changes in Retinal, Retinal Pigment Epithelial, or Choroidal Disease
US20150110372A1 (en) * 2013-10-22 2015-04-23 Eyenuk, Inc. Systems and methods for automatically generating descriptions of retinal images

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12458278B2 (en) 2015-12-23 2025-11-04 Coloplast A/S Moisture assessment system and method for wound care
US11872154B2 (en) 2017-12-22 2024-01-16 Coloplast A/S Medical appliance system, monitor device, and method of monitoring a medical appliance
US11654043B2 (en) 2017-12-22 2023-05-23 Coloplast A/S Sensor assembly part and a base plate for a medical appliance and a method for manufacturing a base plate or a sensor assembly part
US11547595B2 (en) 2017-12-22 2023-01-10 Coloplast A/S Base plate and a sensor assembly part for a medical appliance
US11547596B2 (en) 2017-12-22 2023-01-10 Coloplast A/S Ostomy appliance with layered base plate
US11590015B2 (en) 2017-12-22 2023-02-28 Coloplast A/S Sensor assembly part and a base plate for a medical appliance and a method for manufacturing a sensor assembly part and a base plate
US11589811B2 (en) 2017-12-22 2023-02-28 Coloplast A/S Monitor device of a medical system and associated method for operating a monitor device
US11607334B2 (en) 2017-12-22 2023-03-21 Coloplast A/S Base plate for a medical appliance, a monitor device and a system for a medical appliance
US11612509B2 (en) 2017-12-22 2023-03-28 Coloplast A/S Base plate and a sensor assembly part for an ostomy appliance
US11612508B2 (en) 2017-12-22 2023-03-28 Coloplast A/S Sensor assembly part for a medical appliance and a method for manufacturing a sensor assembly part
US11622719B2 (en) 2017-12-22 2023-04-11 Coloplast A/S Sensor assembly part, base plate and monitor device of a medical system and associated method
US11628084B2 (en) 2017-12-22 2023-04-18 Coloplast A/S Sensor assembly part and a base plate for a medical appliance and a device for connecting to a base plate or a sensor assembly part
US11627891B2 (en) * 2017-12-22 2023-04-18 Coloplast A/S Calibration methods for medical appliance tools
US12208030B2 (en) 2017-12-22 2025-01-28 Coloplast A/S Ostomy appliance system, monitor device, and method of monitoring an ostomy appliance
US11701248B2 (en) 2017-12-22 2023-07-18 Coloplast A/S Accessory devices of a medical system, and related methods for communicating leakage state
US11707376B2 (en) 2017-12-22 2023-07-25 Coloplast A/S Base plate for a medical appliance and a sensor assembly part for a base plate and a method for manufacturing a base plate and sensor assembly part
US11707377B2 (en) 2017-12-22 2023-07-25 Coloplast A/S Coupling part with a hinge for a medical base plate and sensor assembly part
US11717433B2 (en) 2017-12-22 2023-08-08 Coloplast A/S Medical appliance with angular leakage detection
US11730622B2 (en) 2017-12-22 2023-08-22 Coloplast A/S Medical appliance with layered base plate and/or sensor assembly part and related methods
US11534323B2 (en) 2017-12-22 2022-12-27 Coloplast A/S Tools and methods for placing a medical appliance on a user
US11786392B2 (en) 2017-12-22 2023-10-17 Coloplast A/S Data collection schemes for an ostomy appliance and related methods
US11819443B2 (en) 2017-12-22 2023-11-21 Coloplast A/S Moisture detecting base plate for a medical appliance and a system for determining moisture propagation in a base plate and/or a sensor assembly part
US11844718B2 (en) 2017-12-22 2023-12-19 Coloplast A/S Medical device having a monitor mechanically and electrically attachable to a medical appliance
US11540937B2 (en) 2017-12-22 2023-01-03 Coloplast A/S Base plate and sensor assembly of a medical system having a leakage sensor
US11865029B2 (en) 2017-12-22 2024-01-09 Coloplast A/S Monitor device of a medical system having a connector for coupling to both a base plate and an accessory device
US12004990B2 (en) 2017-12-22 2024-06-11 Coloplast A/S Ostomy base plate having a monitor interface provided with a lock to hold a data monitor in mechanical and electrical connection with electrodes of the base plate
US12433782B2 (en) 2017-12-22 2025-10-07 Coloplast A/S Ostomy appliance with selective sensor points and related methods
US12232999B2 (en) 2017-12-22 2025-02-25 Coloplast A/S Base plate and a sensor assembly part for an ostomy appliance
US11974938B2 (en) 2017-12-22 2024-05-07 Coloplast A/S Ostomy system having an ostomy appliance, a monitor device, and a docking station for the monitor device
US11986418B2 (en) 2017-12-22 2024-05-21 Coloplast A/S Medical system and monitor device with angular leakage detection
US11998473B2 (en) 2017-12-22 2024-06-04 Coloplast A/S Tools and methods for cutting holes in a medical appliance
US12433781B2 (en) 2017-12-22 2025-10-07 Coloplast A/S Tools and methods for placing an ostomy appliance on a user
US11918506B2 (en) 2017-12-22 2024-03-05 Coloplast A/S Medical appliance with selective sensor points and related methods
US12178737B2 (en) 2017-12-22 2024-12-31 Coloplast A/S Adhesive ostomy base plate having a sensor assembly adapted to monitor a condition of the adhesive
US12364621B2 (en) 2017-12-22 2025-07-22 Coloplast A/S Ostomy system operable to inform an ostomate of an ostomy device condition useful in preventing leakage relative to the ostomy device
US12064369B2 (en) 2017-12-22 2024-08-20 Coloplast A/S Processing schemes for an ostomy system, monitor device for an ostomy appliance and related methods
US12097141B2 (en) 2017-12-22 2024-09-24 Coloplast A/S Medical system having a monitor attachable to an ostomy appliance and to a docking station
US12127966B2 (en) 2017-12-22 2024-10-29 Coloplast A/S Base plate and sensor assembly of an ostomy system having a leakage sensor
US12138074B2 (en) 2017-12-22 2024-11-12 Coloplast A/S Monitor device of an ostomy system and associated method for operating a monitor device
US12290466B2 (en) 2017-12-22 2025-05-06 Coloplast A/S Accessory devices of an ostomy system, and related methods for communicating leakage state
US12161581B2 (en) 2017-12-22 2024-12-10 Coloplast A/S Method of monitoring performance of an ostomy device with a monitor device attachable to both an ostomy appliance and an accessory device
US12272449B2 (en) 2017-12-22 2025-04-08 Coloplast A/S Data transmission schemes for a medical system, monitor device for a medical appliance and related methods
US12171572B2 (en) 2017-12-22 2024-12-24 Coloplast A/S Accessory devices of a medical system, and related methods for communicating operating state
US12178740B2 (en) 2017-12-22 2024-12-31 Coloplast A/S Leakage detection in an ostomy device
US12178739B2 (en) 2017-12-22 2024-12-31 Coloplast A/S Ostomy appliance having an electrical connector
US12178736B2 (en) 2017-12-22 2024-12-31 Coloplast A/S Ostomy system base plate including electrical terminals and a coupling part attachable to a monitor device
CN111655151A (zh) * 2018-01-25 2020-09-11 国立大学法人大阪大学 压力状态的检测方法以及压力检测装置
CN111655151B (zh) * 2018-01-25 2024-03-22 国立大学法人大阪大学 压力状态的检测方法以及压力检测装置
US12029582B2 (en) 2018-02-20 2024-07-09 Coloplast A/S Accessory devices of a medical system, and related methods for changing a medical appliance based on future operating state
US12208029B2 (en) 2018-02-20 2025-01-28 Coloplast A/S Base plate having a mechanical and electrical connector
US11931285B2 (en) 2018-02-20 2024-03-19 Coloplast A/S Sensor assembly part and a base plate for a medical appliance and a device for connecting to a base plate and/or a sensor assembly part
US12226229B2 (en) 2018-03-15 2025-02-18 Coloplast A/S Methods of configuring ostomy notifications and related accessory devices
US12484845B2 (en) 2018-03-15 2025-12-02 Coloplast A/S Methods for managing remaining wear time of a medical appliance and related accessory devices
US12453649B2 (en) 2018-03-15 2025-10-28 Coloplast A/S Apparatus and methods for determining medical appliance wear time based on location data
US11998474B2 (en) 2018-03-15 2024-06-04 Coloplast A/S Apparatus and methods for navigating ostomy appliance user to changing room
US12232997B2 (en) 2018-08-15 2025-02-25 Coloplast A/S Accessory device of a medical system and related methods for issue identification
US12165312B2 (en) 2018-12-20 2024-12-10 Coloplast A/S Ostomy condition classification with masking, devices and related methods
US12064258B2 (en) 2018-12-20 2024-08-20 Coloplast A/S Ostomy condition classification with image data transformation, devices and related methods
US12376984B2 (en) 2019-01-31 2025-08-05 Coloplast A/S Stomal sensor patch
US12310877B2 (en) 2019-01-31 2025-05-27 Coloplast A/S Sensor patch for an ostomy appliance
US11737907B2 (en) 2019-01-31 2023-08-29 Coloplast A/S Moisture detecting base plate for an ostomy appliance and a system for determining moisture propagation in a base plate and/or a sensor assembly part
US12232998B2 (en) 2019-01-31 2025-02-25 Coloplast A/S Application of a stomal sensor patch
US12257172B2 (en) 2019-02-28 2025-03-25 Coloplast A/S Sensor patch for attachment to a base plate
US12147357B2 (en) 2020-04-14 2024-11-19 Coloplast A/S Personal care system with monitor device and related methods

Similar Documents

Publication Publication Date Title
WO2017136696A1 (fr) Procédés et appareil destinés au traitement de biomarqueurs ophtalmiques
Kim et al. Machine learning based hierarchical classification of frontotemporal dementia and Alzheimer's disease
Li et al. Artificial intelligence in ophthalmology: The path to the real-world clinic
Xue et al. AI-based differential diagnosis of dementia etiologies on multimodal data
Hwang et al. Artificial intelligence-based decision-making for age-related macular degeneration
Jack Jr et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
Csernansky et al. Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects
Kawagoe et al. Subjective memory complaints are associated with altered resting-state functional connectivity but not structural atrophy
JP7600138B2 (ja) 病状によって影響を受ける可能性がある被験者を識別するための方法およびシステム
US8548823B2 (en) Automatically determining ideal treatment plans for complex neuropsychiatric conditions
EP3656289A1 (fr) Système de test de fonction cérébrale et dispositif associé
Nishioka et al. Diffusion tensor imaging reveals visual pathway damage in patients with mild cognitive impairment and Alzheimer's disease
Endo et al. A machine learning–based approach to discrimination of tauopathies using [18F] PM‐PBB3 PET images
EP3901963B1 (fr) Procédé et dispositif permettant d'estimer la progression précoce de la démence à partir d'images de tête humaine
Lillemark et al. Brain region’s relative proximity as marker for Alzheimer’s disease based on structural MRI
WO2010140288A1 (fr) Système d'aide au diagnostic, procédé d'aide au diagnostic de ce système, et dispositif de traitement d'informations
Biousse et al. Application of a deep learning system to detect papilledema on nonmydriatic ocular fundus photographs in an emergency department
Martínez-Torteya et al. Improved diagnostic multimodal biomarkers for Alzheimer’s disease and mild cognitive impairment
Vural et al. Retinal degeneration is associated with brain volume reduction and prognosis in radiologically isolated syndrome
Bhasin et al. A combination of 3-D discrete wavelet transform and 3-D local binary pattern for classification of mild cognitive impairment
Jian et al. Prediction of cognitive decline in Parkinson's disease based on MRI radiomics and clinical features: A multicenter study
US20220000428A1 (en) Method for determining a prediction model, method for predicting the evolution of a k-uplet of mk markers and associated device
Szanto et al. Deep Learning Approach Readily Differentiates Papilledema, Non-Arteritic Anterior Ischemic Optic Neuropathy, and Healthy Eyes
Bhujbal et al. Recent diagnostic techniques for the detection of alzheimer’s disease: a short review
Zhang et al. White matter biomarker for predicting de novo Parkinson’s disease using tract-based spatial statistics: a machine learning-based model

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17748253

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17748253

Country of ref document: EP

Kind code of ref document: A1